STUELPNAGEL JOHN R sold $1.2M of TXG
STUELPNAGEL JOHN R sold 20,000 shares of 10x Genomics, Inc. (TXG) at an average of $61.75 ($60.66–$62.61, $1.24M total) across 3 trades on 2026-09-03.
How this was made
The 30-second read
Why it matters
The disclosed sale is the first public report of this transaction, providing new data on insider holdings.
Market read
Insider sale adds modest new information; limited trading relevance.
What to watch
Potential tax planning or diversification motives not disclosed.
Background
10x Genomics is a leading provider of genomic analysis tools; insider transactions are regularly disclosed via Form 4.
Ticker impact
Director John R. Stuelpnagel sold 20,000 shares of 10x Genomics for $1.23M on 2026-09-03, reducing his holdings to 328,436 shares.
Potential slight downward pressure; no immediate large move expected.
Director sales are common; $1.2M is not material for a mid-cap like 10x Genomics, so market reaction likely muted.
Market effects
Minimal impact on genomics sector; no broader industry signal.
None
None
Counterpoint
The sale could be a routine portfolio rebalancing rather than a negative signal.
Key entities
- DirectorJohn R. Stuelpnagel
Director of 10x Genomics who sold shares.
- Company10x Genomics, Inc.
Biotech company listed on NASDAQ under ticker TXG.
